Broad Institute Awarded $100M to Launch Psychiatric Research Center
News Mar 16, 2007
The Stanley Medical Research Institute has announced a $100M donation to the Broad Institute of MIT and Harvard to launch a research center that will combine the strengths of genomics and chemical biology to advance the understanding and treatment of severe mental illnesses.
The grant will support the creation of the Stanley Center for Psychiatric Research, funding research at the center over the next 10 years.
Based at the Broad Institute, the Stanley Center will be an interdisciplinary center that will bring together scientists from diverse fields and institutions to pursue collaborative projects. It will build upon the Broad Institute’s current psychiatric disease research, which includes work on schizophrenia, bipolar disorder, and major depression and unites leading neuroscience and clinical psychiatry researchers at MIT and Harvard.
The grant will allow a major expansion of these programs as well as the initiation of new programs.
“Schizophrenia and bipolar disorder are among the most devastating psychiatric diseases in America,” said Michael Knable, executive director of the Stanley Medical Research Institute.
“Identifying the biological underpinnings of these illnesses requires diverse scientific skills and a robust spirit of collaboration. The Broad Institute is the ideal place for this important work, because of its collaborative environment, scientific excellence and expertise in genomics and chemical biology,” Knable added.
“Psychiatric disease is an enormous research challenge, because you can’t study it in cell culture like cancer, or measure it with a blood test like diabetes,” said Eric S. Lander, director of the Broad Institute.
“Psychiatric disease may be the most important application for genomics. Genomic tools can help uncover the molecular mechanisms of the disease, which is essential knowledge for developing therapeutics. The Stanley gift is a crucial step toward that goal,” Lander continued.
The Stanley Center for Psychiatric Research springs from the Broad Institute’s Psychiatric Disease Initiative, which includes MIT neuroscience researchers at the Picower Institute for Learning and Memory, McGovern Institute for Brain Research, Whitehead Institute for Biomedical Research and Department of Brain and Cognitive Sciences, and Harvard neuroscience and clinical psychiatry researchers at the Massachusetts General Hospital and McLean Hospital.
The Stanley Center will be directed by Edward Scolnick, who founded the Broad Institute’s Psychiatric Disease Initiative.
“Thanks to the far-reaching vision and unprecedented generosity of the Stanley family, we now have an opportunity to bring powerful new tools to bear on devastating psychiatric diseases,” said Scolnick. “This work would not be possible without the extraordinary caliber and expertise of the MIT and Harvard community. We are grateful for their involvement and eagerly anticipate the scientific fruits of our shared effort.”
Ted Stanley, 75, founder of the Stanley Institute, said, “This is exciting to my wife and me because it gives hope that a partnership with Broad, MIT and Harvard will accelerate our efforts to help people with serious mental illnesses”.
The major projects that will be undertaken at the Stanley Center for Psychiatric Research include systematic surveys of the human genome to identify genes that contribute to schizophrenia and bipolar disorder, and high-throughput chemical screens to uncover modes of treatment.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.